The most recent data from the LIBRA study, which explored ctDNA dynamics in BRAF V600E-mutant NSCLC treated with first-line dabrafenib plus trametinib, used ddPCR (QX200 Droplet Digital PCR) across all samples and NGS (AVENIO ctDNA Expanded Kit) at baseline and progression. This evidence concerns the gene BRAF and non-small cell lung carcinoma.